<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648865</url>
  </required_header>
  <id_info>
    <org_study_id>17756</org_study_id>
    <secondary_id>J2S-MC-GZMA</secondary_id>
    <nct_id>NCT04648865</nct_id>
  </id_info>
  <brief_title>A Study of LY3537031 in Healthy Participants</brief_title>
  <official_title>A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3537031 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of LY3537031 in&#xD;
      healthy participants. The blood tests will be performed to check how much LY3537031 gets into&#xD;
      the bloodstream, how long the body takes to eliminate it and how body handles LY3537031. Each&#xD;
      participant will receive a single dose of LY3537031 or placebo. The study will last up to&#xD;
      approximately 71 days for each participant, including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Actual">June 4, 2021</completion_date>
  <primary_completion_date type="Actual">June 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through final follow-up at approximately Day 43</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3537031</measure>
    <time_frame>Baseline through final follow-up at approximately Day 43</time_frame>
    <description>PK: AUC of LY3537031</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3537031</measure>
    <time_frame>Baseline through final follow-up at approximately Day 43</time_frame>
    <description>PK: Cmax of LY3537031</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3537031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3537031 administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3537031</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3537031</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are male or female not of childbearing potential&#xD;
&#xD;
          -  Have a body mass index (BMI) between 19 and 35 kilograms per square meter (kg/m²) and&#xD;
             a body weight ≥ 54 kilograms (kg)&#xD;
&#xD;
          -  Have blood pressure, pulse rate, blood and urine laboratory test results that are&#xD;
             acceptable for the study&#xD;
&#xD;
          -  Have veins suitable for blood sampling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have or used to have health problems or laboratory test results or ECG readings that,&#xD;
             in the opinion of the doctor, could make it unsafe to participate, or could interfere&#xD;
             with understanding the results of the study&#xD;
&#xD;
          -  Have a diagnosis or history of cancer or malignant disease within 5 years&#xD;
&#xD;
          -  Have been treated with prescription and over-the-counter medications that promote&#xD;
             weight loss within 3 months prior to screening&#xD;
&#xD;
          -  Show clinical evidence of syphilis, HIV, hepatitis C, or hepatitis B, and/or test&#xD;
             positive&#xD;
&#xD;
          -  Have undergone any form of bariatric surgery&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study&#xD;
&#xD;
          -  Are currently participating in or completed a clinical trial within the last 3 months&#xD;
&#xD;
          -  Regularly use known drugs of abuse or with positive drug results&#xD;
&#xD;
          -  Smoke &gt;10 cigarettes per day or the equivalent, or are unable or unwilling to refrain&#xD;
             from nicotine during CRU admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Hospital Tokyo</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 15, 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

